Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
MENT Gel
Product Overview
Alternative Name:
MENT Transdermal Gel
Development Status:
Inactive
Target:
Male
Mode:
Hormonal
Delivery Type:
Transdermal
Duration Type:
Short-acting
Description:
MENT is a synthetic androgen that resembles testosterone. MENT binds to androgen receptors with greater binding affinity than testosterone and dihydrotestosterone, the two active endogenous androgens. The higher binding affinity results in higher bioactivity so that the total dose can be reduced compared to the dose of testosterone required for daily use.
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
7alpha-Methyl-19-Nortestosterone
Inactive material:
Ethanol and other absorption enhancers
Potential Multi-Purpose Technology (MPT):
No
Regimen:
daily
Partner:
Population Council
Status
Project Phase:
Early Development
Project Stage:
Phase I
Began discovery in:
1995
Status Details:
Early studies indicated that MENT gel suppressed steroid sex hormones over a seven-day treatment period, and that the effect was reversible when treatment ended.
MENT was licensed to Schering AG, Germany for replacement therapy in 2001. After the acquisition by Bayer, the company decided to close the program.
Programmatic Considerations
Additional Information
Footnotes:
See also entry on MENT Implant.
Download Product Report
